A9: Role of Galectin-3 in Breast carcinoma chemoresistance
1COLLEGE OF MEDICINE-UAE UNIVERSITY, ALAIN, United Arab Emirates,2DEPARTMENT OF SURGERY-TAWAM HOSPITAL, ALAIN, United Arab Emirates,3DEPARTMENT OF ONCOLOGY-TAWAM, ALAIN, United Arab Emirates
Breast carcinoma is the most common malignant neoplasm and the second cause of cancer death in women worldwide. It is the commonest cancer among UAE. Galectin-3 (GAL-3) is a member of the beta-galactoside-binding family and plays a role in cell proliferation, adhesion, and migration. This project is aimed at carrying out a prospective study to determine the role of GAL-3 in breast cancer chemoresistance
In total, 77 cases of breast carcinoma that have been treated with neoadjuvant chemotherapy were selected for this study. Routine Hematoxylin & Eosin stain was done to evaluate the presence of cancer in pre-neo-adjuvant sections. This evaluation includes identification of histological type, grade and lympho-vascular invasion. In addition we assess the histologic sections of post-neo-adjuvant specimens for grade, and the amount in percentage of the residual tumor.
Five-um sections were also prepared from selected cases paraffin blocks and immunohistochemical staining for GAL-3, bcl2, p-Akt1, and cleaved caspase-3 were done on 75 cases, using streptavidin-biotin immuneperoxidase method.
Pathologic complete response was identified in 27% of cases while incomplete response was noticed in 73% of cases. There is increase in the expression of GAL-3, bcl2, Akt1 in residual malignant cells. The increased expression of GAL-3 in residual tumor cells is associated with increased expression of anti-apoptotic bcl2 and p-Akt1 and low cleaved caspase 3 activity. There is a significant correlation between the expression of GAL-3 in breast carcinoma and resistance to chemotherapy. Chi squared equals 9.561 with 1 degrees of freedom. The two-tailed P =0.0020*.
GAL-3 plays an important role in breast cancer chemoristence